Delivery Order 36F79718D0566-36C26124N0750
Award Date
7/2/24
Potential Completion Date
8/2/24
Potential Value
$22K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Biogen U.s. Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Biogen U.S. Corporation, a biotechnology company focused on developing therapies for neurological diseases. It is a delivery order against Biogen's Pharmaceuticals and Drugs GSA Schedule contract, with a firm-fixed-price of $10,869.15. The contract is for the pharmaceutical product QALSODY (TOFERSEN), which is likely used to treat neurological conditions in veterans. This order was placed by...
This federal contract award to Biogen U.S. Corporation is for the delivery of the pharmaceutical product QALSODY (tofersen) to the U.S. Department of Veterans Affairs (VA). The $21,738.30 firm fixed price delivery order is placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract. The contract has no set-aside designation, indicating Biogen competed against other vendors to secure this award. Biogen U.S. Corporation is a subsidiary of Biogen Idec Incorporated that focuses on...
This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract. The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $10,869.15 delivery order to Biogen U.S. Corporation under the company's Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule contract. The firm fixed price order is for QALSODY (TOFERSEN) 6.7MG SOLN NDC: 64406-0109-01, with an anticipated completion date of April 13, 2024. Place of performance will be in Cambridge, Massachusetts. No set-aside designation was used for this order....
This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of...
This federal contract award is a delivery order for PHARMACY ADVATE ANTIHEMOPHILIC FACTOR, RECOMBINANT 2000UNT/VIL INJ, placed by the Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs General Services Administration (GSA) Schedule. The prime contractor is Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $16,175.70 and no set-aside designation. This award represents a task order under a larger...
The Department of Veterans Affairs Veterans Health Administration awarded Neurocrine Biosciences, Inc. a $608,584.32 firm fixed price delivery order against the company's GSA Schedule Pharmaceuticals and Drugs contract. The delivery order, which runs from August 25-27, 2020, is for the drug valbenazine and will support the VA-VHA's Veterans Integrated Service Network 12 located in San Diego, California. Valbenazine is used to treat tardive dyskinesia, an involuntary movement disorder...
The Department of Veterans Affairs Veterans Health Administration awarded a $676,204.80 firm fixed price delivery order to Neurocrine Biosciences, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The contract calls for Neurocrine to provide valbenazine to Veterans Integrated Service Network 12 in support of the VA-VHA's healthcare programs. Performance will take place in San Diego, California over a period of four days from October 8-12, 2020. No subcontractors or set...
The Department of Veterans Affairs Veterans Health Administration awarded a $652,376 delivery order to Neurocrine Biosciences, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The order calls for the delivery of VALBENAZINE 80MG capsules to the Hines VA Medical Center in Illinois. The one-week period of performance from November 3 to November 10, 2020 indicates this was likely an urgent order to treat veterans for a condition addressed by the medication. Neurocrine...
The Department of Veterans Affairs (VA) Veterans Health Administration and Veterans Integrated Service Network 12 awarded a firm fixed price delivery order contract to Acorda Therapeutics, Inc., a biotechnology company that develops drugs to improve therapies for conditions such as multiple sclerosis, spinal cord injury, and Parkinson's disease. The contract, valued at $485,835.00, is for the delivery of DALFAMPRIDINE, a medication used to improve mobility in multiple sclerosis patients. This...